Trials / Completed
CompletedNCT02473016
Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia
A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Capnia, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A placebo-controlled, single-blind study to evaluate the safety and preliminary efficacy of nasal carbon dioxide for the symptomatic treatment of classical trigeminal neuralgia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carbon Dioxide Drug Delivery System (CDDS) | Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\]. |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2017-03-01
- Completion
- 2017-04-01
- First posted
- 2015-06-16
- Last updated
- 2017-11-17
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02473016. Inclusion in this directory is not an endorsement.